S&P 500   4,704.47 (+0.38%)
DOW   35,787.51 (+0.19%)
QQQ   399.00 (+0.29%)
AAPL   174.23 (+1.78%)
MSFT   332.86 (-0.62%)
FB   331.48 (+2.69%)
GOOGL   2,948.23 (+0.10%)
AMZN   3,526.50 (+0.09%)
TSLA   1,070.65 (+1.80%)
NVDA   318.87 (-1.67%)
BABA   125.18 (-0.29%)
NIO   35.01 (+5.71%)
CGC   10.94 (+2.82%)
AMD   144.41 (-0.30%)
GE   98.40 (+0.87%)
MU   86.25 (+0.49%)
T   23.13 (+0.22%)
F   19.85 (-0.55%)
DIS   153.30 (+1.65%)
PFE   51.43 (-0.56%)
AMC   32.37 (+4.28%)
ACB   6.59 (+3.29%)
BA   211.02 (+1.05%)
S&P 500   4,704.47 (+0.38%)
DOW   35,787.51 (+0.19%)
QQQ   399.00 (+0.29%)
AAPL   174.23 (+1.78%)
MSFT   332.86 (-0.62%)
FB   331.48 (+2.69%)
GOOGL   2,948.23 (+0.10%)
AMZN   3,526.50 (+0.09%)
TSLA   1,070.65 (+1.80%)
NVDA   318.87 (-1.67%)
BABA   125.18 (-0.29%)
NIO   35.01 (+5.71%)
CGC   10.94 (+2.82%)
AMD   144.41 (-0.30%)
GE   98.40 (+0.87%)
MU   86.25 (+0.49%)
T   23.13 (+0.22%)
F   19.85 (-0.55%)
DIS   153.30 (+1.65%)
PFE   51.43 (-0.56%)
AMC   32.37 (+4.28%)
ACB   6.59 (+3.29%)
BA   211.02 (+1.05%)
S&P 500   4,704.47 (+0.38%)
DOW   35,787.51 (+0.19%)
QQQ   399.00 (+0.29%)
AAPL   174.23 (+1.78%)
MSFT   332.86 (-0.62%)
FB   331.48 (+2.69%)
GOOGL   2,948.23 (+0.10%)
AMZN   3,526.50 (+0.09%)
TSLA   1,070.65 (+1.80%)
NVDA   318.87 (-1.67%)
BABA   125.18 (-0.29%)
NIO   35.01 (+5.71%)
CGC   10.94 (+2.82%)
AMD   144.41 (-0.30%)
GE   98.40 (+0.87%)
MU   86.25 (+0.49%)
T   23.13 (+0.22%)
F   19.85 (-0.55%)
DIS   153.30 (+1.65%)
PFE   51.43 (-0.56%)
AMC   32.37 (+4.28%)
ACB   6.59 (+3.29%)
BA   211.02 (+1.05%)
S&P 500   4,704.47 (+0.38%)
DOW   35,787.51 (+0.19%)
QQQ   399.00 (+0.29%)
AAPL   174.23 (+1.78%)
MSFT   332.86 (-0.62%)
FB   331.48 (+2.69%)
GOOGL   2,948.23 (+0.10%)
AMZN   3,526.50 (+0.09%)
TSLA   1,070.65 (+1.80%)
NVDA   318.87 (-1.67%)
BABA   125.18 (-0.29%)
NIO   35.01 (+5.71%)
CGC   10.94 (+2.82%)
AMD   144.41 (-0.30%)
GE   98.40 (+0.87%)
MU   86.25 (+0.49%)
T   23.13 (+0.22%)
F   19.85 (-0.55%)
DIS   153.30 (+1.65%)
PFE   51.43 (-0.56%)
AMC   32.37 (+4.28%)
ACB   6.59 (+3.29%)
BA   211.02 (+1.05%)
NYSE:NVRO

Nevro Stock Forecast, Price & News

$95.47
-0.06 (-0.06%)
(As of 12/8/2021 03:37 PM ET)
Add
Compare
Today's Range
$93.89
$96.14
50-Day Range
$84.90
$126.63
52-Week Range
$84.17
$188.14
Volume
7,125 shs
Average Volume
489,076 shs
Market Capitalization
$3.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.06
30 days | 90 days | 365 days | Advanced Chart
Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.


Nevro logo

About Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Headlines

Nevro (NYSE:NVRO) Sets New 52-Week Low at $84.17
November 29, 2021 |  americanbankingnews.com
Nevro (NYSE:NVRO) Sets New 1-Year Low at $86.01
November 22, 2021 |  americanbankingnews.com
Nevro (NYSE:NVRO) Rating Reiterated by SVB Leerink
November 21, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
843
Year Founded
N/A

Sales & Book Value

Annual Sales
$362.05 million
Book Value
$9.15 per share

Profitability

Net Income
$-83.07 million
Pretax Margin
-27.28%

Debt

Price-To-Earnings

Miscellaneous

Free Float
33,996,000
Market Cap
$3.33 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/07/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

2.28 out of 5 stars

Medical Sector

312th out of 1,394 stocks

Surgical & Medical Instruments Industry

32nd out of 126 stocks

Analyst Opinion: 4.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Nevro (NYSE:NVRO) Frequently Asked Questions

Is Nevro a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Nevro stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View analyst ratings for Nevro
or view top-rated stocks.

How has Nevro's stock price been impacted by Coronavirus (COVID-19)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVRO shares have decreased by 13.0% and is now trading at $95.59.
View which stocks have been most impacted by COVID-19
.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Nevro
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) released its quarterly earnings results on Sunday, November, 7th. The medical equipment provider reported ($0.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.01. The medical equipment provider earned $93.21 million during the quarter, compared to analyst estimates of $91.59 million. Nevro had a negative trailing twelve-month return on equity of 24.68% and a negative net margin of 27.51%. The business's quarterly revenue was down 14.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.29) earnings per share.
View Nevro's earnings history
.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its fourth quarter 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $94 million-$98 million, compared to the consensus revenue estimate of $111.49 million.

What price target have analysts set for NVRO?

14 brokers have issued 12-month price targets for Nevro's shares. Their forecasts range from $104.00 to $205.00. On average, they anticipate Nevro's share price to reach $130.83 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price.
View analysts' price targets for Nevro
or view top-rated stocks among Wall Street analysts.

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • D. Keith Grossman, Chairman, President & Chief Executive Officer
  • Patrick Schmitz, Vice President-Operations
  • Roderick H. MacLeod, Chief Financial Officer
  • David Caraway, Chief Medical Officer
  • Christopher Christoforou, Vice President-Technical Operations

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.50%), Invesco Ltd. (4.04%), Capital Research Global Investors (3.92%), Franklin Resources Inc. (2.62%), Wellington Management Group LLP (1.91%) and Geode Capital Management LLC (1.61%). Company insiders that own Nevro stock include Andrew H Galligan, D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro
.

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Wolverine Asset Management LLC, Voya Investment Management LLC, BNP Paribas Asset Management Holding S.A., Goldman Sachs Group Inc., Franklin Resources Inc., Natixis, Victory Capital Management Inc., and Deutsche Bank AG. Company insiders that have sold Nevro company stock in the last year include Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro
or view top insider-selling stocks.

Which institutional investors are buying Nevro stock?

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Capital Research Global Investors, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Wellington Management Group LLP, MARSHALL WACE ASIA Ltd, Massachusetts Financial Services Co. MA, and ArrowMark Colorado Holdings LLC. Company insiders that have bought Nevro stock in the last two years include D Keith Grossman, Elizabeth H Weatherman, and Kashif Rashid.
View insider buying and selling activity for Nevro
or or view top insider-buying stocks.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $95.59.

How much money does Nevro make?

Nevro has a market capitalization of $3.34 billion and generates $362.05 million in revenue each year. The medical equipment provider earns $-83.07 million in net income (profit) each year or ($3.12) on an earnings per share basis.

How many employees does Nevro have?

Nevro employs 843 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

Where are Nevro's headquarters?

Nevro is headquartered at 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at [email protected].


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.